tedisamil

Tedisamil is an investigational class III antiarrhythmic small molecule developed primarily for the treatment of atrial fibrillation and atrial flutter. It acts as a potassium channel blocker, prolonging action potential duration and the QT interval in cardiac tissue. Tedisamil blocks multiple types of potassium channels in the heart, resulting in slowed heart rate and more efficient repolarization in atrial muscle compared to ventricular muscle. It also exhibits significant anti-ischemic properties and was initially investigated for angina pectoris before its antiarrhythmic effects were discovered. Tedisamil is administered intravenously and has a half-life of approximately 8–13 hours[1][2][4][5][6].

Brand names

Pulzium

Other names

tedisamil